Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "Piwowar, Agnieszka" wg kryterium: Autor


Wyświetlanie 1-2 z 2
Tytuł:
Quercetin influences BSA alpha-helical structures of native, ACR- and NaNO2-modified BSAs
Autorzy:
Rorbach-Dolata, Anna
Żurawska-Płaksej, Ewa
Piwowar, Agnieszka
Powiązania:
https://bibliotekanauki.pl/articles/895290.pdf
Data publikacji:
2018-12-31
Wydawca:
Polskie Towarzystwo Farmaceutyczne
Tematy:
albumin
quercetin
nitrosylation
alkylation
conformational changes
circular dichroism
Opis:
Quercetin (QUE) is a plant flavonoid with a multifarious spectrum of properties. It is a prominent component of the human diet, considered to be safe and beneficial for human health. Acrylamide (ACR) and sodium nitrate III (NaNO2) are also present in the diet and may demonstrate adverse and toxic effects on the macromolecules and tissues of the human organism. Albumin, the most abundant blood protein, is the most susceptible to the action of various exogenous factors, which may lead to structural damage and functional disturbances. The aim of this study was to estimate ACR- and NaNO2-induced changes in the secondary structure of bovine serum albumin (BSA), using circular dichroism (CD), and to determine the impact of quercetin on these modifications. BSA was incubated with ACR and NaNO2 solutions in the absence and presence of QUE in two different concentrations (3 mM and 500 µM), and changes in albumin alpha-helical structure were determined by CD. BSA secondary structure was vulnerable to alterations upon treatment with acrylamide and NaNO2, as well as quercetin. QUE, depending on concentration and incubation time, caused a decrease of around 13-19% in the alpha-helix content of BSA molecules, but also prevented the changes in the protein alpha-helical structure initiated by ACR and NaNO2. The most spectacular inhibition was revealed for QUE in lower concentrations after 24h of incubation with NaNO2. Although QUE reveals protective effect towards albumin modifications, it is difficult to unambiguously define whether this effect is advantageous, because quercetin itself causes alterations in BSA structure.
Źródło:
Acta Poloniae Pharmaceutica - Drug Research; 2018, 75, 6; 1339-1346
0001-6837
2353-5288
Pojawia się w:
Acta Poloniae Pharmaceutica - Drug Research
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
INSIGHTS INTO MYCOBACTERIAL ACTIVITY AND CYTOTOXICITY OF SUBSTITUED ISOXAZOLE-4-CARBOHYDRAZIDE DERIVATIVES.
Autorzy:
Płoszaj, Paulina
Junka, Adam
Szponar, Bogumiła
Mączyński, Marcin
Ryng, Stanisław
Bartoszewicz, Marzenna
Piwowar, Agnieszka
Powiązania:
https://bibliotekanauki.pl/articles/895364.pdf
Data publikacji:
2018-06-30
Wydawca:
Polskie Towarzystwo Farmaceutyczne
Tematy:
5-amino-3-methyl-4-isoxazolecarboxylic acid hydrazide
Mycobacterium fortuitum
Opis:
The purpose of this study was to evaluate the antimycobacterial activity of novel derivatives of 5-amino-3-methyl-4-isoxazolecarboxylic acid hydrazide 1, isoniazid (INH) structural analogue. A set of 5-amino-3-methyl-4-isoxazolecarboxylic acid hydrazide 1 derivatives 2a-j have been obtained by condensation reactions with aldehydes and further transformed by cyclization with corresponding orthoesters to 5-amino-3-methylisoxazole[5,4-d]pyrimidin-4-one derivatives 3a-j and 4a-j. From the structural and functional point of view, all these products proved to be biologically important and could be used as substrates for further synthesis. 21 out of 31 structures were newly developed. Described compounds were screened against Mycobacterium fortuitum in MABA test. The most active compound 2e, 2g revealed minimum inhibitory concentration at 16 μg/ml. In addition, these compounds revealed low cytotoxicity against lung (A549) and fibroblasts (L929) cell lines. The results demonstrated the potential and importance of further development of 5-amino-3-methyl-4-isoxazolecarboxylic acid hydrazide derivatives as a new class of antimycobacterial compounds.
Źródło:
Acta Poloniae Pharmaceutica - Drug Research; 2018, 75, 3
0001-6837
2353-5288
Pojawia się w:
Acta Poloniae Pharmaceutica - Drug Research
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-2 z 2

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies